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Abstract
Background: Patients with infective endocarditis (IE) have an elevated risk of renal dysfunction because of
extensive systemic inflammation and use of nephrotoxic antibiotics. In this randomized, placebo-controlled trial, we
investigated whether perioperative sodium bicarbonate administration could attenuate postoperative renal
dysfunction in patients with IE undergoing cardiac surgery.
Methods: Seventy patients randomly received sodium chloride (n = 35) or sodium bicarbonate (n = 35). Sodium
bicarbonate was administered as a 0.5 mmol/kg loading dose for 1 h commencing with anesthetic induction,
followed by a 0.15 mmol/kg/h infusion for 23 h. The primary outcome was peak serum creatinine (SCr) level during
the first 48 h postoperatively. The incidence of acute kidney injury, SCr level, estimated glomerular filtration rate,
and major morbidity endpoints were assessed postoperatively.
Results: The peak SCr during the first 48 h postoperatively (bicarbonate vs. control: 1.01 (0.74, 1.37) mg/dl vs. 0.88
(0.76, 1.27) mg/dl, P = 0.474) and the incidence of acute kidney injury (bicarbonate vs. control: 29% vs. 23%, P = 0.
584) were similar in both groups. The postoperative increase in SCr above baseline was greater in the bicarbonate
group than in the control group on postoperative day 2 (0.21 (0.07, 0.33) mg/dl vs. 0.06 (0.00, 0.23) mg/dl, P = 0.028)
and postoperative day 5 (0.23 (0.08, 0.36) mg/dl vs. 0.06 (0.00, 0.23) mg/dl, P = 0.017).
Conclusions: Perioperative sodium bicarbonate administration had no favorable impact on postoperative renal
function and outcomes in patients with IE undergoing cardiac surgery. Instead, it was associated with possibly
harmful renal effects, illustrated by a greater increase in SCr postoperatively, compared to control.
Trial registration: ClinicalTrials.gov, NCT01920126. Registered on 31 July 2013.
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Background
For the treatment of infective endocarditis (IE), recent
evidence favors early surgical intervention to reduce the
risk of stroke and death [1, 2]. Surgery with cardiopul-
monary bypass (CPB), however, is inevitably accompan-
ied by numerous factors that contribute to acute kidney
injury (AKI) [3]. An early, exaggerated inflammatory re-
sponse with oxidative stress and the preoperative use of
nephrotoxic antibiotics further predispose patients with
IE to renal impairment [4–6]. Indeed, AKI affects up to
60% of patients with IE undergoing cardiac surgery [6],
and the occurrence and severity of AKI have been indis-
putably associated with mortality and poor outcomes [7].
Sodium bicarbonate has been demonstrated to protect
the kidneys through urinary alkalization and increasing
the tubular pH [8, 9]. It reduces the pH-dependent con-
version of hemoglobin to methemoglobin and production
of free radicals via the Haber-Weiss reaction [10, 11].
* Correspondence: ylkwak@yuhs.ac
1Department of Anesthesiology and Pain Medicine, Yonsei Cardiovascular
Hospital, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu,
Seoul 120-752, Republic of Korea
2Anesthesia and Pain Research Institute, Yonsei University College of
Medicine, Seoul, Republic of Korea
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cho et al. Critical Care  (2017) 21:3 
DOI 10.1186/s13054-016-1591-z
After a pilot study reported that with sodium bicarbonate
infusion there was a reduced incidence of AKI after car-
diac surgery [8], numerous clinical trials evaluated its
renoprotective efficacy in different types of surgery and
patients, yielding conflicting results [12–15]. Considering
the massive oxidative stress associated with systemic in-
flammation and prolonged use of nephrotoxic antibiotics
in patients with IE [16], the abilities of sodium bicarbonate
to attenuate oxidative stress may prove especially helpful
in preventing AKI in these patients. However, most previ-
ous studies investigating the renal effects of sodium bicar-
bonate have excluded patients with systemic infection,
and no study has heretofore been conducted solely in pa-
tients with IE. The aim of this prospective, randomized,
placebo-controlled trial was to investigate the effect of
perioperative sodium bicarbonate administration on post-
operative renal function in patients with IE undergoing
cardiac surgery with CPB.
Methods
The study protocol was approved by the Institutional
Review Board and Hospital Research Ethics Committee
of Severance Hospital at Yonsei University College of
Medicine (#4-2013-0376) and registered at Clinical-
Trials.gov on July 2013 (NCT01920126). The trial was
conducted at Yonsei University College of Medicine in
Seoul, Korea, between August 2013 and July 2016. After
providing written informed consent, 70 patients between
20 and 80 years old, who were scheduled for valvular heart
surgery for IE, were enrolled. IE was diagnosed according
to the modified Duke criteria [17]. Patients were excluded
if they met at least one of these criteria preoperatively: (1)
estimated glomerular filtration rate (eGFR) <15 ml/min/
1.73 m2; (2) receiving renal replacement therapy; (3) re-
ceiving intra-aortic balloon pump support; (4) preexisting
hypernatremia, alkalosis, or severe pulmonary edema; or
(5) chronic moderate dose to high dose corticosteroid
therapy (>10 mg/day prednisolone or equivalent).
Enrolled patients were randomly assigned to either the
control or bicarbonate group at a 1:1 ratio using a
computer-generated random-number table. Assignments
were concealed in sealed envelopes. The study drugs
were prepared in identical 50-ml syringes by an
anesthesia nurse not involved with the study. The bicar-
bonate group received 154 mEq/l sodium bicarbonate
with a 0.5 mmol/kg intravenous (IV) loading dose over
1 h immediately after anesthetic induction, followed by
an IV continuous infusion at 0.15 mmol/kg/h over 23 h.
The control group received equivalent volumes of IV
0.9% sodium chloride for the same duration. Attending
surgeons and anesthesiologists involved in patient man-
agement in the operating room and intensive care unit
(ICU) were blinded to the group assignment. Group as-
signment was disclosed after hospital discharge.
All patients received institutionally standardized
anesthetic care and CPB management as previously de-
scribed [18]. Intraoperatively, all patients received bal-
anced crystalloid (Plasma solution A 1000 inj, CJ, Seoul,
Korea) at 6 ml/kg/h and balanced synthetic colloid
(Volulyte; Fresenius Kabi, Bad Homburg, Germany) to
replace estimated blood loss (to a maximum of 500 ml).
Mean arterial pressure (MAP) <70 mm Hg was treated
with norepinephrine, with the infusion starting at 0.01 μg/
kg/min and titrated to a maximum of 0.3 μg/kg/min. If
the blood pressure was not maintained with norepineph-
rine, vasopressin was infused at 2.4–4.0 units/h. Milrinone
(0.5 μg/kg/min) was infused when the mixed venous oxy-
gen saturation decreased below 60% for >10 minutes.
Postoperatively, when urine output was <1 ml/kg/h for
30 minutes, loop diuretics were administered after a
200-ml IV bolus of crystalloid. If this was inadequate,
fluid boluses were repeated up to three times. If urine
output remained inadequate 15 minutes after the
third bolus, 5 mg of IV furosemide was administered
and then repeated every 30 minutes, with escalating
doses until the desired effect (urine output >1 ml/kg/h)
was achieved. Renal replacement therapy was initiated if
any of the following occurred: refractory oliguria (urine
output <0.5 ml/kg/h for 12 h), fluid overload, hyperkale-
mia (>6.5 mEq/l), rapidly rising serum potassium level,
signs of uremia, or metabolic acidosis (pH <7.10).
Outcome measures
The primary outcome measure was the difference in
peak serum creatinine (SCr) level between groups during
the first 48 h postoperatively. We assumed that >0.3 mg/dl
difference in SCr would be clinically significant, based on
the Acute Kidney Injury Network (AKIN) criteria [19]. Sec-
ondary outcomes included the incidence of postoperative
AKI (diagnosed by the AKIN criteria) [19], electrolyte ab-
normalities, major morbidity endpoints, ICU and hospital
length of stay, and in-hospital mortality. Changes in
SCr and eGFR, which were measured before surgery,
upon ICU arrival, and at least once per day until
postoperative day (POD) 5, were assessed. Serum so-
dium (Na+), potassium (K+), bicarbonate, and pH
were measured before surgery and at 6 and 24 h after
commencing the study drug infusion. The incidence
of hypernatremia (serum (Na+) >150 mmol/l), hypokal-
emia (serum (K+) <3.5 mmol/l), or alkalemia (serum
pH >7.50) was determined. The major morbidity end-
points were permanent stroke, hemostatic re-exploration,
AKI, prolonged ventilator care (>48 h), and deep sternal
wound infection.
Preoperative variables included demographics, pre-
operative morbidities, left ventricular ejection fraction,
Cleveland Clinic score [20], and EuroSCORE. Factors as-
sociated with an increased risk of renal injury in patients
Cho et al. Critical Care  (2017) 21:3 Page 2 of 9
with IE were investigated [6]. Intraoperative variables
included the surgery duration, CPB and aortic cross-
clamp times, fluid balance, transfusion requirements,
and vasoconstrictor/inotropic medication requirements.
Hemodynamic variables, including heart rate (HR), MAP,
mean pulmonary arterial pressure (MPAP), central venous
pressure (CVP), and cardiac index (CI), were recorded
15 minutes after anesthetic induction, 15 minutes after
weaning from CPB, at sternum closure, upon ICU arrival,
and at 24 h and 48 h after surgery. Postoperative variables
included fluid balance, urine output, blood loss (chest tube
drainage), packed erythrocyte transfusion, and vasocon-
strictor/inotrope usage during the first 48 h after surgery.
Body temperature, C-reactive protein level, white blood
cell count, and percentage of neutrophils were measured
before surgery and at least once per day until POD 5.
Statistical analysis
The standard deviation (SD) of SCr level at 48 h postop-
eratively was previously reported as 0.4 in patients
undergoing valvular heart surgery at our institute [18].
We estimated that 29 patients in each group would be
required to detect a mean difference of 0.3 and SD of
0.4 in peak SCr levels during the first 48 h postopera-
tively, with 80% power at a significance level of P <0.05.
Factoring in a 20% dropout rate, we enrolled 35 patients
in each group.
Data are shown as mean ± SD, median (interquartile
range), or number. Between-group comparisons of con-
tinuous variables were performed using the independent
t test or Mann-Whitney U test, after testing for normal-
ity using the Kolmogorov-Smirnov test. Dichotomous
variables were compared using chi-square test or Fisher’s
exact test. Serially measured variables were analyzed
using a linear mixed model with patient indicator as a
random effect and group, time, and group-by-time as
fixed effects. This was followed by post hoc analysis
using the Bonferroni correction. All statistical analyses
were two-tailed and performed using SPSS 20 software
(SPSSFW, SPSS Inc., IBM, Armonk, NY, USA). P <0.05
was considered statistically significant.
Results
Of the 70 patients enrolled, IE was definitively con-
firmed through surgical findings and pathologic examin-
ation in 32 patients in each group. According to the
intention-to-treat principle, statistical analyses were per-
formed using data from all enrolled patients. Four pa-
tients in each group (P > 0.999) underwent emergency
surgery within 24 h after being diagnosed with IE. All
patients were treated with antibiotics before the day of
surgery. At the time of surgery, 29 (83%) and 27 (77%)
patients in the bicarbonate and control groups, respect-
ively, had active infection with a positive blood culture,
leukocytosis (>10,800/μl), fever (temperature >38 °C), or
elevated C-reactive protein (>8 mg/l) (P = 0.550). The time
between diagnosis of IE and surgery was similar in both
groups (bicarbonate vs. control: 11 (5, 17) days vs. 8 (5,
17) days, P = 0.857). All baseline patient characteristics
were comparable in the two groups, except that more
patients received anti-platelet drugs prior to surgery
(5 vs. 0, P = 0.020) and had platelet counts below 150,000/
μl (11 vs. 3, P = 0.017) in the control group (Table 1).
Renal outcomes
The peak SCr level during the first 48 h postoperatively
was not significantly different between groups (bicarbon-
ate vs. control: 1.01 (0.74, 1.37) mg/dl vs. 0.88 (0.76,
1.27) mg/dl, P = 0.474). The postoperative increase in
SCr above baseline was significantly greater in the bicar-
bonate group than in the control group on POD 2 (0.21
(0.07, 0.33) mg/dl vs. 0.06 (0.00, 0.23) mg/dl, P = 0.028)
and POD 5 (0.23 (0.08, 0.36) mg/dl vs. 0.06 (0.00, 0.23)
mg/dl, P = 0.017). Postoperative SCr levels were higher
and eGFR values were lower in the bicarbonate group than
in the control group, but the group × time interactions for
the SCr level and eGFR during the five PODs were not sta-
tistically significant between groups in the linear mixed-
model analysis (P = 0.055 and 0.073, respectively).
There were no differences in the incidence of AKI
(bicarbonate vs. control: 29% vs. 23%, P = 0.584) or dis-
tribution of AKIN stages (P = 0.863) between groups
(Table 2). No patient, except one who received renal re-
placement therapy in the control group, was oliguric
(<0.5 ml/kg/h) for more than 6 h and thus fulfilled the
definition of AKI according to the urine output-based
AKIN criteria. Of note, using another set of diagnostic
criteria for AKI [8, 15, 21] (increase in SCr >25% or
0.5 mg/dl from baseline), the incidence of AKI was sig-
nificantly higher in the bicarbonate group than in the
control group (60% vs. 31%, P = 0.016).
Fluid balance, vasopressor/inotrope requirements,
electrolytes, and hemodynamics
Intraoperative fluid balance, transfusion requirements,
and use of vasoconstrictor/inotropic medications were
similar in both groups, except that fewer patients received
platelet transfusions in the bicarbonate group (P = 0.023)
(Table 3). Changes in perioperative hemodynamic vari-
ables, including HR (P = 0.699), MAP (P = 0.950), MPAP
(P = 0.361), CVP (P = 0.409), and CI (P = 0.939), were
comparable in the two groups in the linear mixed-model
analysis (see Additional file 1 for more detail).
Postoperative fluid balance, transfusion requirements,
and use of vasoconstrictor/inotropic medications during
the first 48 h after surgery were comparable in both
groups, except that fewer patients received erythrocyte
transfusions during the first 24 h after surgery in the
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bicarbonate group (P = 0.048) (Table 4). The incidence
rates of alkalemia (20% vs. 11%, P = 0.324), hypernatre-
mia (0% vs. 3%, P = 0.314), and hypokalemia (17% vs.
14%, P = 0.743) during the five PODs were similar in
both groups.
Non-renal postoperative outcomes
Changes in body temperature (P = 0.621), C-reactive pro-
tein level (P = 0.611), white blood cell count (P = 0.511),
and percentage of neutrophils (P = 0.539) during the five
PODs were similar in both groups (see Additional file 2
Table 1 Demographic and perioperative clinical data
Control group (n = 35) Bicarbonate group (n = 35) P value
Demographics
Age (years) 55.1 ± 15.7 53.9 ± 14.1 0.738
Sex (male:female) 27:8 21:14 0.122
Body mass index (kg/m2) 21.6 ± 3.6 22.0 ± 3.3 0.613
Cormobidities
Hypertension 10 10 >0.999
Diabetes mellitus 6 4 0.495
Congestive heart failure 1 0 0.314
Chronic kidney disease (SCr >1.4 mg/dl) 7 8 0.771
MI within 1 month 0 0
Cerebrovascular disease 5 3 0.452
COPD 0 0
Repeat surgery 4 6 0.495
Preoperative condition
Left ventricular ejection fraction (%) 63.9 ± 8.5 65.9 ± 7.4 0.312
EuroSCORE 4 (2, 9) 5 (3, 8) 0.449
Cleveland Clinic scorea 2 (1, 3) 2 (1, 2) 0.360
Vancomycin or aminoglycoside 27 29 0.550
Contrast use 48 h prior to surgery 19 14 0.231
Hemoglobin below 10 g/dl 14 8 0.122
Platelets below 100,000/μl /150,000/μl 3/ 11 1/ 3 0.303/0.017
Embolic events 8 13 0.192
Prosthetic valve infection 4 6 0.495
Active infectionb/emergencyc 27/ 4 29/ 4 0.555/>0.999
Medications
ACEi/ARB 8 8 >0.999
β-blockers 7 8 0.771
Calcium channel blockers 3 4 0.690
Diuretics 12 14 0.621
Antiplatelet drugs 5 0 0.020
Operation
Aortic valve replacement 11 7 0.274
Mitral valve replacement 17 19 0.632
Double valve operation 4 2 0.393
Tricuspid annuloplasty 2 3 0.643
Valve + aorta 1 4 0.164
Values are mean ± standard deviation, number of patients, or median (interquartile range). SCr serum creatinine, MI myocardial infarction, COPD chronic
obstructive lung disease, ACEi angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, CABG coronary artery bypass graft; aCleveland Clinic
Foundation Acute Renal Failure Scoring System (minimum score = 0; maximum score = 17); bactive infection, patients exhibiting an active infection with a positive
blood culture, leukocytosis (>10,800/μl), fever (>38 °C), or C-reactive protein >8 mg/l; cemergency, patients undergoing emergency operation within 24 h after
being diagnosed with infective endocarditis
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for more detail). The incidence of a composite of morbid-
ity endpoints (P = 0.621) and the ICU and hospital length
of stay were also similar in the two groups. Two patients
in the control group died during their hospital stay be-
cause of cerebral hemorrhage, whereas no mortality oc-
curred in the bicarbonate group (Table 5).
Discussion
In this prospective, randomized, placebo-controlled trial
we did not observe any beneficial effects of perioperative
bicarbonate administration on postoperative renal func-
tion in patients with IE undergoing cardiac surgery with
CPB. Sodium bicarbonate did not attenuate the peak
postoperative SCr level nor reduce the incidence of AKI
defined by the AKIN criteria. In fact, the postoperative
increase in SCr above baseline was even greater in the
bicarbonate group than in the control group.
Acute IE is a challenging disease that is associated
with high morbidity and mortality. Although most pa-
tients with IE undergo medical treatment, more than
20% require surgery, and the number of surgical treat-
ments has gradually increased as accumulating evidence
supports the use of cardiac surgery to improve outcomes
[1, 2]. However, morbidity and mortality following car-
diac surgery in patients with IE remain significant. AKI
is one of the most common morbidities, with a rate of
20–60% [6, 22]. Moreover, AKI clearly increases long-
term postoperative mortality and cardiac event rates in
patients with IE [6, 23], but definitive strategies to
prevent AKI in this patient population have not been
established.
The systemic inflammation and oxidative stress associ-
ated with septic conditions predispose patients with IE
undergoing cardiac surgery to AKI [5]. Furthermore,
prolonged use of nephrotoxic antibiotics preoperatively,
and administration of contrast media shortly before car-
diac surgery, adds to the risk of AKI by enhancing proin-
flammatory oxidative stress [16, 24]. Sodium bicarbonate
administration produces blood and urine alkalization
and may slow pH-dependent Haber-Weiss free-radical
production, thereby attenuating reactive oxygen species-
mediated tubular injury [11, 24, 25]. Sodium bicarbonate
may also directly scavenge other reactive species [26].
Tubular alkalosis achieved by sodium bicarbonate has been
demonstrated to mitigate the conversion of hemoglobin to
methemoglobin, preventing tubular obstruction and tubu-
lar cell necrosis [10]. Accordingly, sodium bicarbonate ad-
ministration has shown benefits in experimental models of
ischemic [27], doxorubicin-induced [28], and contrast-
medium-induced AKI [29]. However, several trials and
meta-analyses investigating the renal effects of sodium
bicarbonate in the context of cardiac surgery yielded
Table 2 Incidence of postoperative acute kidney injury, serum creatinine level and glomerular filtration rate
Control group (n = 35) Bicarbonate group (n = 35) P value
Serum creatinine (mg/dl)*
before surgery 0.90 ± 0.36 0.83 ± 0.24 0.055
immediately after surgery 0.83 ± 0.36† 0.73 ± 0.22†
at 24 h after surgery 0.99 ± 0.35† 1.01 ± 0.41†
at 48 h after surgery 0.94 ± 0.38 1.13 ± 0.65†
at 72 h after surgery 0.89 ± 0.38 1.08 ± 0.70†
at 120 h after surgery 0.84 ± 0.32 0.99 ± 0.65
Glomerular filtration rate (ml/min per 1.73 m2)*
before surgery 89.6 ± 34.6 94.1 ± 36.9 0.073
immediately after surgery 96.5 ± 43.4† 102.4 ± 42.2
at 24 h after surgery 79.3 ± 35.1† 79.6 ± 39.3†
at 48 h after surgery 85.7 ± 40.5 75.2 ± 38.6†
at 72 h after surgery 91.1 ± 40.3 81.2 ± 40.0†
at 120 h after surgery 94.7 ± 36.8 86.0 ± 42.4
AKIN classification
None (n) 27 (77%) 25 (71%) 0.863
Stage 1 (n) 6 (17%) 6 (17%)
Stage 2 (n) 1 (3%) 2 (6%)
Stage 3 (n) 1 (3%) 2 (6%)
Any category 8 (23%) 10 (29%) 0.584
Values are mean ± standard deviation or numbers (%). Postoperative acute kidney injury (AKI) was diagnosed according to the Acute Kidney Injury Network (AKIN)
classification. *P value demonstrates the value for the group × time interaction in the linear mixed model; †P < 0.05 vs. baseline value
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inconsistent results [8, 14, 15, 21]. Based on the theoretical
ability of sodium bicarbonate to reduce oxidative stress in
renal tubular cells, we investigated whether perioperative
sodium bicarbonate infusion would lessen renal injury in
this patient population, an issue that has not been previ-
ously addressed.
Contrary to our expectation, sodium bicarbonate infu-
sion did not demonstrate renoprotective effects in this
study. The postoperative peak SCr level and incidence of
AKI defined by the AKIN criteria were similar in both
groups. Indeed, when AKI was diagnosed using the cri-
teria that were applied in the first trial reporting reno-
protective effects of sodium bicarbonate in cardiac
surgery (increase in SCr >0.5 mg/dl or 25% above base-
line) [8], the incidence of AKI was significantly greater
in the bicarbonate group than in the control group.
Moreover, the increase in postoperative SCr levels above
baseline was significantly greater in the bicarbonate
group than in the control group.
These results imply that the effects of sodium bicar-
bonate on renal function may not just be neutral, but
they may even be harmful in patients with IE undergo-
ing cardiac surgery, which argues against the routine use
of sodium bicarbonate. Notably, intraoperative platelet
transfusion requirement was higher in the control group
than in the bicarbonate group, which might be attributed
to the fact that more patients received anti-platelet drugs
(5 vs. 0, P = 0.020) and had platelet counts below
150,000/μl (11 vs. 3, P = 0.017) in the control group. In
addition, packed erythrocyte transfusion requirement
during the 24 h postoperatively was also higher in the
control group than in the bicarbonate group. Erythrocyte
and platelet transfusions are associated with an in-
creased risk of AKI and dialysis [30, 31]. Thus, the
higher incidence of AKI in the bicarbonate group despite
less transfusion further supports the possibly harmful
impact of bicarbonate infusions.
In the context of cardiac surgery, previous findings
demonstrate that the renoprotective effects of sodium
bicarbonate were limited to low-risk patients [12, 32].
Furthermore, a recent trial of prophylactic sodium bicar-
bonate therapy to prevent AKI in high-risk patients was
terminated early because of increased mortality in the
bicarbonate group [15]. This difference according to the
patient’s risk is consistent with our results, as our pa-
tients had a high risk of AKI because of infection, severe
inflammation, receipt of nephrotoxic antibiotics, and
surgery-related injury. The likelihood of postoperative
AKI is higher in patients with more risk factors [6], and a
single treatment strategy might be insufficient to attenuate
renal injury in patients with multiple risk factors. This
might be the most cogent explanation for our results.
The inability of sodium bicarbonate to reduce AKI was
discussed from the perspective of alkalemia and resultant
Table 3 Intraoperative data
Control group (n = 35) Bicarbonate group (n = 35) P value
Operation time (minutes) 227.9 ± 67.0 211.8 ± 94.5 0.412
Anesthesia time (minutes) 270.7 ± 78.0 265.5 ± 105.6 0.815
Cardiopulmonary bypass time (minutes) 118.7 ± 51.8 109.6 ± 75.1 0.554
Aortic cross-clamp time (minutes) 87.3 ± 43.3 77.6 ± 56.5 0.424
Fluid balance
Crystalloid (ml) 1000 (775, 1200) 1000 (600, 1375) 0.995
Colloid (ml) 130 (100, 300) 100 (100, 200) 0.288
Urine output (ml) 870 (560, 1240) 1000 (600, 1250) 0.526
Ultrafiltration during CPB (ml)/ na 2000 (1250, 2400)/25 1550 (1300, 2100)/26 0.216/0.788
Transfusion
Amount of cell saver (ml) 500.0 (477.5, 740.0) 500.0 (480.0, 730.0) 0.652
Amount of erythrocyte (unit) 1 (0, 2) 1 (0, 2) 0.916
Patients transfused with erythrocyte 21 21 >0.999
Patients transfused with FFP 18 17 0.811
Patients transfused with PLT 12 4 0.023
Vasopressor/ Inotrope needs
Norepinephrine dose (μg/kg/min) 0.03 (0.01, 0.04) 0.02 (0.01, 0.05) 0.317
Patients needed vasopressin 16 14 0.629
Patients needed milrinone 4 4 >0.999
Values are mean ± standard deviation, median (interquartile range), or number of patients. aNumber of patients receiving ultrafiltration during cardiopulmonary
bypass (CPB). FFP fresh frozen plasma, PLT platelet
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physiologic changes in previous studies [13–15]. Alkale-
mia can lead to impaired tissue perfusion [33, 34] and
oxygen delivery [35], and to increased cell death and
apoptosis associated with superoxide formation [36]. Most
patients enrolled in our study had active inflammation
and received prolonged treatment with multiple nephro-
toxic antibiotics, which would aggravate renal injury
associated with increased renal vascular resistance
and tubular cell impairment [5, 37, 38]. During active
systemic inflammation, increased renal vascular resistance
(uncoupled from decreased systemic vascular resistance)
may diminish renal perfusion, thereby causing ische-
mia [5, 38]. Indeed, multiple areas of renal infarction
were observed in an animal model of IE, suggesting
hypoperfusion-induced ischemia [39]. Nephrotoxic antibi-
otics have also been demonstrated to reduce renal blood
flow by increasing renal vascular resistance rather than by
lowering perfusion pressure [40]. Alkalosis following
Table 5 Postoperative outcomes
Control group (n = 35) Bicarbonate group (n = 35) P value
Composite of morbidity endpoints 14 (40%) 12 (34%) 0.621
Permanent stroke 3 (9%) 0 0.077
Hemostatic reoperation 5 (14%) 4 (11%) 0.721
Acute kidney injury 8 (23%) 10(29%) 0.584
Ventilator care >48 h 2 (6%) 2 (6%) >0.999
Deep sternal wound infection 1 (3%) 1 (3%) >0.999
In-hospital mortality 2 (6%) 0 0.151
Duration of ventilator care (h) 17 (13, 20) 15 (10, 22)] 0.448
Duration of intensive care unit stay (days) 2 (2, 3) 2 (1, 3) 0.361
Duration of hospital stay (days) 28 (17, 35) 26 (15, 32) 0.350
Values are number of patients (%) or median (interquartile range)
Table 4 Postoperative input, output, and vasoconstrictor use
Control group (n = 35) Bicarbonate group (n = 35) P value
Crystalloid input (ml)
during postoperative 24 h 2550 (2000, 3374) 2250 (1850, 3170) 0.226
during postoperative 48 h 1950 (1420, 2565) 1990 (1065, 2550) 0.450
Colloid input (ml)
during postoperative 24 h 340 (100, 500) 280 (0, 420) 0.157
during postoperative 48 h 0 (0, 0) 0 (0, 0) 0.196
Urine output (ml)
during postoperative 24 h 3225 (2420, 3610) 2790 (2205, 3530) 0.375
during postoperative 48 h 2800 (2190, 3515) 2490 (1700, 3915) 0.597
Chest tube drainage (ml)
during postoperative 24 h 230 (150, 523) 200 (144, 311) 0.372
during postoperative 48 h 160 (90, 336) 130 (70, 280) 0.269
Erythrocyte (unit) transfusion
during postoperative 24 h (n)a 0 (0, 1) (17) 0 (0, 1) (9) 0.076 (0.048)
during postoperative 48 h (n)a 0 (0, 0) (4) 0 (0, 0) (5) 0.724 (0.721)
Norepinephrine (μg/kg/min)
during postoperative 24 h 0.02 (0.01, 0.03) 0.02 (0.01, 0.05) 0.860
during postoperative 48 h 0.02 (0.01, 0.02) 0.04 (0.04, 0.08) 0.200
Patients needed milrinone (n)
during postoperative 24 h 9 6 0.382
during postoperative 48 h 3 4 0.690
Values are mean ± standard deviation, median (interquartile range), or number of patients. aNumber of patients requiring transfusion
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sodium bicarbonate infusion could further increase renal
vascular resistance [34] and exacerbate renal tubular in-
jury by producing intracellular acidosis. A rapid influx of
CO2 following sodium bicarbonate infusion could worsen
intracellular acidosis [41], accelerating the influx of so-
dium and calcium, and causing cell swelling and renal tu-
bule dysfunction [42].
There has been a paucity of randomized, controlled
trials in patients with IE undergoing cardiac surgery.
This may be at least partly because these patients are
often unstable or require urgent surgery, leading to a
preponderance of observational studies. Thus, the pri-
mary strength of this study is that it is the first to ad-
dress the renoprotective efficacy of sodium bicarbonate
through randomization, solely in patients with IE under-
going cardiac surgery, although the sample size was not
sufficient to compare the incidence of AKI, which is the
most clinically relevant index.
The limitations of this study are as follows. First, we
did not directly measure urine pH to confirm urinary
alkalization by IV sodium bicarbonate administration.
However, both plasma and urinary alkalization were
achieved in previous studies using similar doses and du-
rations of sodium bicarbonate infusion [8, 15, 21]. Sec-
ond, we can only speculate on the reasons for the lack
of beneficial effect of sodium bicarbonate in this study,
because no mechanistic investigations were conducted.
Third, we used balanced 130/0.4 hydroxyethyl starch so-
lution (Volulyte) for volume replacement, upon which
concerns have been raised regarding its nephrotoxicity
in patients with sepsis. However, its influence on renal
function is far more controversial when used in the op-
erating theatre. Indeed, there is solid evidence favoring
its use in the presence of overt volume loss [43–45]. Fur-
thermore, the median volume used in this study did not
exceed 500 ml in either group throughout the periopera-
tive 24 h, without any intergroup difference. Thus, its in-
fluence on the observed results should be negligible.
Conclusions
Perioperative sodium bicarbonate administration did not
improve postoperative renal function or other outcomes
in patients with IE undergoing cardiac surgery. Rather, it
was associated with potentially harmful renal effects, as
demonstrated by a greater postoperative increase in SCr
above baseline, compared to control. Further research on
renoprotective strategies in patients with IE is warranted.
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